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To the Editor:
Rheumatoid arthritis (RA) is an autoimmune inflammatory disease that can
be considered as a prothrombotic state1. A great number of studies have
investigated the possible role of reactive oxygen species (ROS) in the
etiology and pathogenesis of this disease. The presence of large amounts of
superoxide radicals and hydrogen peroxide produced by activated
neutrophils has been reported in the synovial fluid of patients with RA. This
may cause lipid peroxidation that yields a wide variety of end products,
including malondialdehyde (MDA), a known marker of oxidative stress.
These products are therefore transported from the synovial fluid to the blood
circulation system2. Considering that elevated levels of MDA have been
observed in the blood plasma of patients with RA2, the aim of this pilot study
was to investigate whether the elevated levels of plasmatic MDA could be
associated with a modification of the total antioxidant capacity (TAC) of
blood plasma that is usually indicative of a “systemic” oxidative imbalance3.
In addition, in view of their activity as redox effectors or scavengers4, as
well as determinants of thrombus formation5, we evaluated red blood cell
(RBC) features in terms of their redox state and lifespan marker molecules.
In our pilot study, 15 women with early RA (median age 44 yrs, range
20–56; median disease duration 24 weeks, range 12–60) and 15 age- and
sex-matched healthy donors (HD) were included. Patients with RA were
diagnosed according to the 2010 criteria of the American College of
Rheumatology and European League Against Rheumatism6. Patients were
excluded from the study if they had congenital heart disease, previous
myocardial infarction, thrombotic events, renal or hepatic dysfunction,
cancer, human immunodeficiency virus infection, or hepatitis. All patients
(1) had active disease, defined as 28-joint Disease Activity Score 4.26 ±
1.27; (2) had not yet been treated for RA; and (3) had no comorbidities, such
as hypertension, hyperglycemia, hypercholesterolemia, or cardiovascular
risk factors. Interestingly, no patients had anemia, and all showed high levels
of C-reactive protein (CRP) and high values of erythrocyte sedimentation
rate (ESR; Figure 1).
The nature and the purpose of our study were explained to all partici-
pants who gave their informed consent following the rules of good medical
practice. This study was approved by the Institutional Review Board of
“Sapienza” University of Rome, Italy, according to the principles outlined
in the Declaration of Helsinki.
Plasma and RBC were isolated by centrifugation of whole blood7. RBC
redox balance (levels of ROS and total thiol content), and expression of
molecules involved in RBC senescence (CD47) and injury [Phosphatidyl-
serine (PS) externalization] were evaluated as previously reported7.
Expression of molecules responsible for RBC survival [survivin and extra-
cellular signal-regulated kinase (ERK)] was evaluated by static (not shown)
and flow cytometry using monoclonal antibodies (Santa Cruz Biotechnology
and BD Biosciences). MDA and TAC were evaluated using commercially
available ELISA immunoassay kits. The Mann-Whitney U test was used to
compare quantitative variables in different groups. Flow cytometry data
were statistically evaluated using the Kolmogorov–Smirnov nonparametric
test7 according to the Cell Quest Pro software guide (BD BioSciences).
In our study, we found that (1) as expected, plasmatic MDA levels were
significantly higher (p < 0.05) in patients with RA (median 2.62 µg/ml, range
1.2–4.3) than in HD (median 1.73 µg/ml, range 0.8–2.6), and (2) TAC of
blood plasma was significantly reduced (p < 0.005) in patients with RA
(median 2.8 mM, range 2.2–5.4) compared to HD (median 21.35 mM, range
3.1–30.4). Interestingly, this does not seem to significantly interfere with
the redox state of RBC and with externalization of PS. In fact, a mild
production of ROS and a mild reduction of total thiol content have been
detected in RBC from patients with RA. Similarly, no differences have been
found in the percentage of RBC showing PS externalization (evaluated in
Figure 1. Evaluation of (A) RBC number, (B)
Hb content, (C) CRP level, and (D) ESR value.
Data are represented as box plots displaying
medians, and 25th and 75th percentiles as boxes.
Whiskers represented the smallest and the
largest non-outlier values. * p < 0.001. RBC: red
blood cells; Hb: hemoglobin; CRP: C-reactive
protein; ESR: erythrocyte sedimentation rate.
RA: rheumatoid arthritis; HD: healthy donors.
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terms of percentage of annexin V-positive RBC; Figure 2A, 2B, and 2C) and
in the expression of CD47 (Figure 2D). Conversely, survivin (p < 0.001;
Figure 2E) and phosphorylated ERK (p < 0.001; Figure 2F) were signifi-
cantly higher in RBC from patients with RA than in those from HD. CD47
is an integrin-associated protein, known as the thrombospondin receptor,
which acts as a marker of self. Survivin is a member of the inhibitor of
apoptotic protein family. ERK is a mitogen-activated protein kinase whose
phosphorylation induces (1) upregulation of survivin8, and (2) increase of
RBC adhesion to the endothelium9. Hence, our data, although obtained in a
small cohort of patients, seem to indicate that in patients with RA, a mild
alteration of intracellular redox state of RBC can occur. This is associated
with activation of ERK signaling pathway and overexpression of survivin.
This possibly leads to alterations of RBC homeostasis that, together with
increased ESR and inflammatory protein CRP10, could alter blood flow1.
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